[ CAS No. 159858-21-6 ]

Name: 159858-21-6|Fmoc-Val-Cit-OH|95%
Brand: Ambeed
SKU: A453269
Price: 11.0 USD
Availability: InStock
Rating: 91 (27 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 159858-21-6 * Storage: {[proInfo.prStorage]}

Cart0 Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 88K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 159858-21-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 159858-21-6 ]

SDS

Alternatived Products of [ 159858-21-6 ]

Product Details of [ 159858-21-6 ]

CAS No. :	159858-21-6	MDL No. :	MFCD28139060
Formula :	C₂₆H₃₂N₄O₆	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	N/A
M.W :	496.56 g/mol	Pubchem ID :	-
Synonyms :

Safety of [ 159858-21-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 159858-21-6 ]

Upstream synthesis route of [ 159858-21-6 ]
Downstream synthetic route of [ 159858-21-6 ]

[ 159858-21-6 ] Synthesis Path-Upstream 1~4

1
[ 159858-21-6 ]
[ 623-04-1 ]
[ 159858-22-7 ]

Yield	Reaction Conditions	Operation in experiment
88%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol; dichloromethane at 20℃; for 48 h; Darkness	DCM/MeOH=2/1 mixed solvent 60 ml was added to the reaction flask, followed by addition of Fmoc-vc2g (4.2 mmol) and1.04 g (2 eq) of PABOH was added. After stirring the dissolved portion, 2.0 g (2 eq) of EEDQ was added. The reaction system is protected from light at room temperatureStir the reaction for 2.0 days. After completion of the reaction, the mixture was concentrated under reduced pressure at 40°C to give a white solid. Collect white solids and add methyl tert-butylEthyl ether (100 ml) was stirred and filtered, and the filter cake was washed with methyl tert-butyl ether. The resulting white solid was dried at 40 °C under reduced pressure to give 2.2 g.About 88percent
85%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol; dichloromethane at 20℃; for 36 h; Darkness; Inert atmosphere	Fmoc-Val-Cit-PABOH 2. To a solution of Fmoc-protected dipeptide 1 (0.30 g, 0.60 mmol) in CH₂Cl₂/MeOH (2: 1 , 9 mL) was added P-aminobenzyl alcohol (0.12 g, 0.98 mmol ) and EEDQ (0.24 g, 0.98 mmol), and the reaction mixture was stirred in the dark for 1.5 d. The solvents were evaporated, and the resultant was triturated with Et₂0 (25 mL). The resulting suspension was sonicated for 20 min and left to stand for 30 min. The crude product was collected by filtration and then purified by flash chromatography using a pre-packed 50 g silica column [solvent A: MeOH; solvent B: CH₂C1₂; gradient: 0percentA / 100percentB (1 CV), 0percentA / 100percentB -→ 20percentA / 80percentB (10 CV), 20percentA / 80percentB (2 CV); flow rate: 40 mL/min; monitored at 254 and 280 nm] to afford Fmoc-protected compound 2 (0.31 g, 0.51 mmol, 85percent yield) as a brown solid. [000188] NMR (500 MHz, DMSO-d6) 6 10.00 (1 H, s), 8.13 (1 H, d, J = 7.7 Hz), 7.92 (2H, d, J = 7.5 Hz), 7.81 - 7.71 (2H, m), 7.57 (2H, d, J= 8.4 Hz), 7.49 - 7.40 (3H, m), 7.35 (2H, t, J= 7.4 Hz), 7.26 (2H, d, J = 8.3 Hz), 5.99 (1 H, t, J = 6.5 Hz), 5.43 (2H, s), 5.12 (1 H, t, J= 5.6 Hz), 4.45 (2H, d, J= 5.4 Hz), 4.32 (1H, d,J= 10.1 Hz), 4.29 - 4.19 (3H, m), 4.00 - 3.88 (1H, m), 3.12 - 2.91 (2H, m), 2.09 - 1.94 (1H, m), 1.80-1.31 (4H, m), 0.90 (3H, d, .7=6.6 Hz), 0.88 (3H, d,J=6.7 Hz). [000189] ^I3C NMR (125 MHz, DMSO-d6) δ 171.7, 170.9, 159.3, 156.6, 144.4, 144.2, 141.2, 138.0, 137.9, 128.1, 127.6, 127.4, 125.8, 120.6, 119.3, 66.2, 63.1, 60.6, 47.2,30.9,30.0, 27.3, 19.7, 18.8, 15.0.
82%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol at 20℃; for 36 h;	Fmoc-val-cit (1 eq),Add 2 eq of p-aminobenzyl alcohol (2 eq) to DMC / MeOH (2: 1), add EEDQ (2 eq) and shake for 1.5 days at room temperature.After completion of the reaction, the solvent is dried and precipitated with ether. Repeat after filtering with Ether. Yield: yellow solid 82percent.

77%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol; dichloromethane at 40℃;	Step 3 Synthesis of (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (92) To the suspension of compound 90 (70 g, 0.141 mol) in DCM/MeOH (1 L/500 mL) was added compound 91 (34.7 g, 0.282 mol) followed by EEDQ (69.7 g, 0.282 mol). The mixture was stirred at 40° C. overnight. The reaction mixture was filtered and the wet cake was suspended in EtOAc/TBME (500 mL/200 mL) and stirred for 30 min, then filtered. The solid was washed with EtOAc/TBME to provide compound 92 as off-white solid 65 g (77percent). ¹H NMR (400 MHz, DMSO-d6) δ=9.98 (s, 1H), 8.11 (d, 1H), 7.87 (d, 2H), 7.77 (m, 2H), 7.52 (d, 2H), 7.39 (m, 3H), 7.30 (m, 2H), 7.21 (d, 2H), 5.97 (m, 1H), 5.41 (s, 2H), 5.10 (m, 1H), 4.42 (m, 3H), 4.22 (m, 3H), 3.90 (m, 1H), 2.93 (m, 2H), 1.98 (m, 1H), 1.50 (m, 2H), 1.30 (m, 2H), 0.84 (m, 6H).
76%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol; dichloromethane at 20℃;	A solution of compound 28 (1 g, 2.01 mmol, leq) andp-aminobenzyl alcohol (273 mg, 2.21 mmol, 1.1 eq) in a mixture of DCM/MeOH (20 mL/10 mL) was treated with EEDQ (996 mg, 4.03 mmol, 2 eq). The mixture was stirred in the dark at room temperature overnight. The solvents were removed under vacuum and the resulting solid residue was triturated with 10 mL of ethyl ether. The solid was collected by filtration and washed with ethyl ether to yield the product (925 mg, 76percent yield): ¹H NMR (DMSO-5 d, J -8.5 Hz), 7.74 (2H, t, J = 6.7 Hz), 7.89 (2H, d, J = 7.6 Hz)₅ 8.12 (IH, d, J = 7.3 Hz); ¹³ C NMR (DMSO-c^) δ 18.34, 19.28, 26.84, 29.56, 30.47, 46.67, 53.05, 60.05, 62.55, 65.65, 118.71, 119.98, 125.23, 126.79, 126.94, 127.51, 137.27, 137.36, 140.55, 143.60, 143.73, 155.93, 158.69, 170.17, 171.06.
65%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In methanol; dichloromethane at 20℃; for 16 h; Darkness	EEDQ (840 mg, 3.4 mmol) is added to a solution containing compound [12] (870 mg, 1 .7 mmol) and p-aminobenzyl alcohol (227 mg, 1 .8 mmol) in dichloro- methane/methanol 2:1 (15 mL). The reaction is left in the dark at room temperature for 16 hours. The solvents are removed, and the resulting solid residue filtrated using diethyl ether to give product [14] as a white solid, 660 mg (65percent yield). MS: m/z 624 [M+Na]⁺.¹H NMR (400 MHz, DMSO) δ 10.00 (bs, 1 H), 8.13 (m, 4H), 7.92 (d, J = 7.3 Hz, 2H), 7.76 (d, J = 7.6 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.51 - 7.10 (m, 2H), 6.02 (s, 1 H), 5.43 (m, 4H), 5.13 (s, 1 H), 4.47 (s, 3H), 4.31 (m 4H), 3.13 - 2.74 (m, 2H), 2.03 (s, 1 H), 1 .83 - 1 .55 (m, 2H), 1 .43 (s, 2H), 0.90 (d, J = 6.7 Hz, 6H).¹³C NMR (101 MHz, DMSO) δ 171 .2, 170.4, 158.93, 156.15, 144.6, 143.8, 140.7, 137.5, 127.6, 127.2 (2C) 125.3, 120.1 (2C), 1 18.9, 65.7, 62.6, 60.1 , 53.0, 46.7, 31 .0, 30.5, 26.7, 19.6, 18.7.

Reference： [1] International Journal of Molecular Sciences, 2017, vol. 18, # 9,
[2] Patent: CN107789630, 2018, A, . Location in patent: Paragraph 0073; 0074; 0075
[3] Patent: WO2017/66668, 2017, A1, . Location in patent: Paragraph 000187-000189
[4] Journal of Controlled Release, 2012, vol. 160, # 3, p. 618 - 629
[5] Patent: KR2017/41562, 2017, A, . Location in patent: Paragraph 0431-0432
[6] Patent: US2016/271270, 2016, A1, . Location in patent: Paragraph 0379; 0382
[7] Patent: WO2008/34124, 2008, A2, . Location in patent: Page/Page column 79
[8] Patent: WO2018/178060, 2018, A1, . Location in patent: Page/Page column 64; 65; 67
[9] Patent: WO2014/80251, 2014, A1, . Location in patent: Sheet 16/23
[10] Bioconjugate Chemistry, 2015, vol. 26, # 11, p. 2261 - 2278
[11] Nature Communications, 2017, vol. 8, # 1,

2
[ 159858-21-6 ]
[ 159857-81-5 ]

Reference： [1] Patent: WO2017/66668, 2017, A1,
[2] Patent: WO2017/66668, 2017, A1,
[3] International Journal of Molecular Sciences, 2017, vol. 18, # 9,
[4] Patent: CN107789630, 2018, A,
[5] Patent: CN108743968, 2018, A,

3
[ 159858-21-6 ]
[ 159857-79-1 ]

Reference： [1] Patent: WO2014/80251, 2014, A1,
[2] Patent: WO2017/66668, 2017, A1,
[3] International Journal of Molecular Sciences, 2017, vol. 18, # 9,
[4] Patent: CN107789630, 2018, A,
[5] Patent: WO2018/178060, 2018, A1,
[6] Patent: CN108743968, 2018, A,

4
[ 159858-21-6 ]
[ 863971-53-3 ]

Reference： [1] Patent: US2016/271270, 2016, A1,

[ 159858-21-6 ] Synthesis Path-Downstream 1~24

1
[ 372-75-8 ]
[ 130878-68-1 ]
[ 159858-21-6 ]

Yield	Reaction Conditions	Operation in experiment
98%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 0 - 20℃; for 28h;	a) Fmoc-Val-Cit-OH (31) To a solution of Fmoc-Val-OSu (1.00 g, 2.29 mmol) and NaHCCh (260 mg, 3.09 mmol) in H2O (7.5 ml.) at 0 C was added a solution of /.-citrulline (501 mg, 2.87 mmol) in DME (7.5 ml_). THF (4 ml.) was added, the reaction warmed to rt and stirred for 28 h. Upon completion, the reaction was adjusted to pH 10 with saturated aqueous K2CO3 and washed with EtOAc (2 x 50 ml_). The aqueous layer was acidified to pH 4 with 15% aqueous citric acid and the formed gelatinous mixture was filtered. The wet cake was redissolved in THF/MeOH (50 ml_), TBME (100 ml.) was added and the mixture was stirred at rt for 16 h. The mixture was filtered and the filtrate concentrated in vacuo to yield Fmoc-Val-Cit-OH (1.12 g, 2.25 mmol, 98%) as an off-white solid.
87%	With sodium hydrogencarbonate; In tetrahydrofuran; water; N,N-dimethyl-formamide; at 20℃;	Citrulline (420 mg, 2.41 mmol) ws combined with solid NaHCC (200 mg, 2.38 mmol) and dissolved in water (6.0 mL). To this mixture ws added a solution of compound 3 (1.0 g, 2.29 mmol) in DMF (6 mL). The mixture was stirred for 5 minutes and THF (5 mL) was added and the reaction mixture was stirred overnight at room temperature. (1042) [0556] A 15% Citric acid solution (1 1.5 mL) wns added to the reaction mixture with stirring and a precipitate formed. The mixture was extracted with a 9: 1 mixture of EtOAc / i-PrOH (3 x 15 mL). the combined organic layers were washed with brine twice, dried over MgS04, filtered and evaporated to dryness to give a residue. The residue was sonicated with ether and iterated. (1043) A white solid formed, which was collected by filtration and dried under vacuum to give 1 0 g for a 87% yield. MS (ESI): mie 496.56 (MH)+, 497, (M + Na)+, 519.
82%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; at 20℃; for 16h;Inert atmosphere;	Fmoc-Val-Cit 1. To a solution of l-citrulline (0.274 g, 1.56 mmol) and NaHC03 (0.131 g, 1 .56 mmol) in water (4 mL) was added a solution of Fmoc-Val-Osu (0.650 g, 1.49 mmol) in DME (4 mL). THF (2 mL) was added to aid solubility, and the reaction mixture was stirred for 16 h at ambient temperature. HC1 (2 M, 8 mL) was added, and the white solid product began to precipitate but remained in the organic layer. The mixture was extracted with isopropanol/EtOAc ( 1 : 9, 2 chi 20 mL), and the combined organic suspension was washed with water (2 chi 20 mL). The resultant suspension was concentrated under reduced pressure, and then treated with Et20 (20 mL). After sonication and trituration with Et20, the crude product was collected by filtration, and the crude product was purified by flash chromatography using a pre-packed 50 g silica column [solvent A: MeOH; solvent B: CH2C12; gradient: 0%A / 100%B (1 CV), 0%A / 100%B? 30%A / 70%B (10 CV), 30%A / 70%B (2 CV); flow rate: 40 mL/min; monitored at 254 and 280 nm] to afford Fmoc-protected dipeptide 1 (0.610 g, 1.22 mmol, 82% yield) as a white solid. [000185] NMR (500 MHz, DMSO-d6) delta 8.18 (1 H, d, J = 7.3 Hz), 7.90 (2H, d, J= 7.5 Hz), 7.75 (2H, t, J= 8.0 Hz), 7.41 (3H, q, J = 8.1 Hz), 7.33 (2H, td, J= 6.6, 3.2 Hz), 5.94 (1H, t, J= 5.5 Hz), 5.38 (2H, bs), 4.33 - 4.26 (1 H, m), 4.26 - 4.19 (2H, m), 4.19 - 4.12 (2H, m), 3.93 (1H, dd, J= 9.0, 7.2 Hz), 2.95 (2H, q, J = 6.6 Hz), 2.04 - 1.92 (1H, m), 1.76 - 1.65 (1 H, m), 1.62 - 1.52 (1H, m), 1.46 - 1.34 (2H, m), 0.89 (3H, d, J= 6.8 Hz), 0.87 (3H, d, J= 6.8 Hz). [000186] 1 C NMR (125 MHz, DMSO-d6) delta 173.9, 171.8, 159.2, 156.5, 144.4, 144.2, 141.2, 128.1 , 127.5, 125.9, 120.6, 66.1 , 60.3, 52.4, 47.1 , 31.0, 28.8, 27.2, 19.7, 18.7.

82%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 20℃; for 6h;	Fmoc-val-NHS (1 eq) was added to DME, and L-citrulline (1.05 eq)NaHCO3 (1.05 eq) is dissolved in water.Add THF to dissolve well and stir for 6 hours at room temperature.After completion of the reaction, the organic layer was separated by separatory funnel using EA (1: 1.25) containing citric acid (15%) aqueous solution and 10% isopropanol,Dry with MgSO4. The resulting solid is vacuum dried for 5 hours, then precipitated with ether and filtered. Yield: yellow solid 82%.
81.7%	With sodium carbonate; In tetrahydrofuran; at 20℃; for 48h;pH 8 - 9;	The 20 g of compound 31 is dissolved in 200 ml of the solvent in the THF, adding 9.64 g (1.2 eq) L - Citrulline, adding 1 M carbonate to pH 8 - 9, the response [...], stirring at the room temperature reaction 48 h, TLC detection reaction is complete. In ice-bath under stirring, aqueous solution of citric acid for adjusting the pH for the reaction solution 3 - 4, isopropyl alcohol: EA=1:5 (40 ml isopropanol + 200 ml EA) extraction 3 times, the organic phase the merger, anhydrous sodium sulfate drying, filtering turns on lathe does, then adding 200 ml of armor uncle ether stirring, the stirring 2 hours after the filtering, the collection filter cake, and placed in a 45 C and dried in the vacuum drying box 18.6 g white solid product, yield by about 81.7%.
74%	With sodium carbonate; In water; acetonitrile; at 0 - 35℃;	Fmoc-Val-OSu (1 eq.) was dissolved in Acetonitrile (5 vol.) at 20C. Separately, sodium carbonate (1.1 eq.) was solubilized in Water (5 vol.) at 20C and L-Citrulline (1.1 eq.) was then added to give a homogeneous clear solution. Water (0.5 vol.) was added to the Fmoc-Val-OSu solution and the reaction mixture was heated to 35C before adding the prepared citrulline solution dropwise over 10 min. The reaction mixture was stirred at 35 C for 3-4 hours until reaction was complete before being cooled to 20C. Acetonitrile (20 vol.) was then added over 2-3 hours at 20C. The resulting suspension was stirred for 1-3 hours before being cooled to 0-5C over 1-4 hours and stirred at that temperature for 2-3 hours. Solids were filtered, washed and dried under vacuum before being re-dissolved in a mixture of N,N-dimethylformamide (3.9 vol.), 35.9 g/L aqueous NaCl solution (3.9 vol.), 10% isopropanol in Ethyl acetate (19.5 vol.) at 20C. Glacial acetic acid (1.3 vol.) was then added and the pH of the solution was adjusted to <2 with concentrated hydrochloric acid (0.78 vol.). After stirring at 20C for 30 minutes, phases were separated and the aqueous layer was re extracted with Ethyl acetate (6.5 vol.). Combined organic layers were washed three times with a mixture of 179.5 g/L aqueous NaCl solution (6.5 vol.) and anhydrous N,N- Dimethylformamide (0.72 vol.). The resulting organic mixture was concentrated to a white paste and diluted with Methanol (19.5 vol.). The resulting suspension is stirred at 20C for 10-14 hours before being concentrated again to a white paste. Methyl tert-butyl ether (19.5 vol.) was then added and the resulting suspension was stirred at 40C for 1-2 hours. After cooling to 20C and stirring followed by cooling to 0-5C and stirring, solids were filtered, washed and dried under vacuum. Solids were re-slurried twice in a mixture of Methanol (1.3 vol.) and Methyl tert-butyl ether (19.5 vol.) and dried under vacuum (74% yield). MS: m/e 497 (MH)+, 519 (M+Na)+.
70%		Fmoc- VaI-NHS (2.5 g, 5.73 mmol, 1 eq) in 15 mL of DME was added to a solution of L- citrulline (1.05 g, 6.01 mmol, 1.05 eq) in 8 mL of THF and NaHCO3 (505 mg, 6.01 mmol, 1.05 eq) in 15 mL of water. The mixture was stirred at room temperature overnight. Aqueous citric acid (75 mL of a 15% solution in water) was added and the mixture was extracted with 10% IP A/EtOAc (2 x 100 mL). The organic layers were washed with water (3 x 100 mL) and the solvent was evaporated under vacuum. The resulting solid was triturated with 100 mL of ethyl ether and filtered to yield the product (1.98 g, 70% yield): 1H NMR (DMSCW0) delta 0.86 (3H, d, J = 6.7 Hz), 0.90 (3H5 d, J = 7.0 Hz), 1.40-1.48 (2H, m), 1.51-1.75 (2H, m), 1.98 (IH, sext, J = 6.8 Hz), 2.95 (2H, q, J = 6.2 Hz), 3.93 (IH, dd, J = 7.3, 8.8 Hz), 4.14-4.29 (4 H, m), 5.40 (2H, brs), 5.96 (IH, t, J = 5.6 Hz), 7.32 (2H, t, J = 7.5 Hz), 7.39-7.44 (3H, m), 7.75 (2H} t, J = 6.3 Hz), 7.89 (2H, d, J = 7.3 Hz), 8.19 (IH, d, J = 7.3 Hz); B C NMR (DMSO-ofc) delta 18.31, 19.25, 26.75, 28.40, 30.59, 46.68, 51.91, 59.81, 64.92, 65.65, 119.98, 125.30, 126.94, 127.52, 140.55, 143.61, 143.76, 155.88, 158.58, 171.12, 173.25.
45%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 20℃; for 16h;	Compound [10] (1 .7 g, 3.9 mmol) in dimethoxyethane (10 ml_) is added to a solution of L-citrulline [1 1 ] (700 mg, 4 mmol) dissolved in a mixture of tetrahydrofuran and aqueous sodium bicarbonate (344 mg, 4 mmol in 10 mL of water). The reaction is stirred at room temperature for 16 hours. A solution of citric acid 15% in water (50 mL) is added and the mixture extracted with 10% isopropyl alcohol in ethyl acetate (2x75 mL). The solvent is removed by rotatory evaporation. After addition of diethyl ether and irradiation with ultrasounds, the formation of a solid is obtained. Filtration followed by washing with diethyl ether gave [12] as a white solid, 870 mg (45%). MS: m/z 495 [M-H]-.1H NMR (400 MHz, DMSO) delta 8.19 (bm 3H), 7.87 (t, J = 25.1 Hz, 2H), 7.77 (t, J = 6.8 Hz, 2H), 7.49 - 7.23 (m, 4H), 5.99 (s, 1 H), 5.43 (s, 2H), 4.45 - 4.08 (m, 4H), 3.97 (t, J = 7.5 Hz, 1 H), 2.99 (d, J = 5.1 Hz, 2H), 2.02 (d, J = 6.1 Hz, 1 H), 1 .74 (s, 1 H), 1 .61 (d, J = 7.5 Hz, 1 H), 1 .44 (s, 2H), 0.91 (dd, J = 12.5, 6.3 Hz, 6H).13C NMR (101 MHz, DMSO) delta 173.4, 171 .3, 169.8, 167.8, 158.8, 156.0, 143.8, 140.7, 127.6, 127.0, 65.7, 59.8, 51 .9, 46.7, 30.5, 26.6, 19.18 (2C).
44.3%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 0 - 20℃; for 24h;	1.2) Cit (0.4g, 2.3mmol) and NaHCO3 (0.19g, 2.3mmol) were co-dissolved in 50mL distilled water, cooled to 0 C, and a 25mL DME solution of Fmoc-Val-OSu (1g, 2.29mmol) was gradually dropped Add to a mixed solution of Cit and NaHCO3, add another 20mL of tetrahydrofuran to help dissolve, and stir at room temperature for 24h to obtain a reaction solution.1.3) In the reaction solution obtained in step 1.2), saturated potassium carbonate was added dropwise to adjust the pH to 8-9, and then extracted three times with 20 mL of ethyl acetate. The aqueous layer was collected, and the citric acid solution was added to adjust the pH to 3-4. A gelatinous solid precipitated, filtered, and a white gel-like solid was dissolved in a mixed solution of 25 mL of tetrahydrofuran and 10 mL of methanol, and concentrated in a 250 mL round-bottomed flask to 10 mL by rotary evaporation, and 200 mL of methyl tert-butyl ether was added and stirred at 0 C overnight , Filtered and dried under vacuum to obtain the product Fmoc-Val-Cit (0.5 g, yield 44.3%) as a white solid.
4.83 g	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 20℃; for 24h;	Add Cit 4.0g (1.05 eq) and 20 ml of THFAn aqueous solution of sodium hydrogencarbonate (60 ml (NaHCO3 2 g, 1.05 eq)).Another 22.35 mmol of Fmoc-Val-OSu was dissolved in 60 ml of DME.This was added to the reaction solution.The reaction solution was stirred at room temperature for 24 hours.After the reaction was completed, 110 ml of a 15% aqueous citric acid solution was added to the system.It was then extracted twice with EA. And 100 ml of methyl tert-butyl ether was added to the white solid and stirred.filter,The filter cake was dried under reduced pressure at 40 C for 4 h to obtain 4.83 g of product.The yield was 65%.
	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 20℃;	The reaction product of the previous step (16 g, 36.6 mmol) was dissolved in 90 mL of DME, and L-Cit (6.7 g, 38.5 mmol) was dissolved in NaHCO3 (3.2 g, 38.5 mmol) in 90 mL of water to form a salt. In the system,50 mL of THF was solubilized and the reaction was stirred at room temperature overnight until clear.After the reaction is completed,An equal volume of 15% aqueous citric acid solution with THF was added under ice bath.The white solid of the reaction product is completely precipitated.The Buchner funnel was suction filtered until the filtrate was clarified, and the filter cake was drained.Dry in a vacuum oven. After drying, the white solid is ground.Wash with ether,Filtering,A white solid was obtained.

Reference： [1]Patent: WO2020/25108,2020,A1 .Location in patent: Page/Page column 48
[2]Patent: WO2020/14541,2020,A2 .Location in patent: Paragraph 0546; 0551; 0555-0556
[3]Patent: WO2017/66668,2017,A1 .Location in patent: Paragraph 000184-000186
[4]Patent: KR2017/41562,2017,A .Location in patent: Paragraph 0428-0429
[5]Patent: CN109125736,2019,A .Location in patent: Paragraph 0113; 0130; 0133; 0134
[6]Patent: WO2019/108797,2019,A1 .Location in patent: Paragraph 0113
[7]Patent: WO2008/34124,2008,A2 .Location in patent: Page/Page column 78
[8]Patent: WO2018/178060,2018,A1 .Location in patent: Page/Page column 64-67
[9]Patent: CN110604820,2019,A .Location in patent: Paragraph 0054; 0057; 0059
[10]Journal of Controlled Release,2012,vol. 160,p. 618 - 629
[11]Patent: WO2014/80251,2014,A1 .Location in patent: Sheet 16/23
[12]Bioconjugate Chemistry,2015,vol. 26,p. 2261 - 2278
[13]Patent: CN108743968,2018,A .Location in patent: Paragraph 0013; 0014; 0015
[14]Patent: CN109200291,2019,A .Location in patent: Paragraph 0051; 0063; 0066

2
[ 159858-21-6 ]
[ 623-04-1 ]
[ 159858-22-7 ]

Yield	Reaction Conditions	Operation in experiment
Ca. 88%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃; for 48h;Darkness;	DCM/MeOH=2/1 mixed solvent 60 ml was added to the reaction flask, followed by addition of Fmoc-vc2g (4.2 mmol) and1.04 g (2 eq) of PABOH was added. After stirring the dissolved portion, 2.0 g (2 eq) of EEDQ was added. The reaction system is protected from light at room temperatureStir the reaction for 2.0 days. After completion of the reaction, the mixture was concentrated under reduced pressure at 40C to give a white solid. Collect white solids and add methyl tert-butylEthyl ether (100 ml) was stirred and filtered, and the filter cake was washed with methyl tert-butyl ether. The resulting white solid was dried at 40 C under reduced pressure to give 2.2 g.About 88%
88%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃; for 48h;Darkness;	Add 60 ml of DCM/MeOH=2/1 mixed solvent to the reaction flask.Add Fmoc-vc 2g (4.2mmol) andPABOH 1.04g (2eq),After stirring the dissolved fraction, EEDQ 2.0 g (2 eq) was added.The reaction system was stirred at room temperature for 2.0 d in the dark.After completion of the reaction, concentration under reduced pressure at 40 C gave a white solid.The white solid was collected and stirred with 100 ml of methyl tert-butyl ether.Filtered, the filter cake was washed with methyl tert-butyl ether.The obtained white solid was dried under reduced pressure at 40 C to give 2.2 g.The yield is about 88%.
87%	With 1-bromo-2,3,4-tri-O-acetyl-alpha-D-glucuronic acid methyl ester; In methanol; dichloromethane; at 20℃; for 48h;Darkness;	The Fmoc-Val-Cit 4 (1.0 g, 2.01 mmol) and p-aminobenzyl alcohol (492 mg, 4.0 mmol) were dissolved in a 1 : 1 solution of dichloromethane / methanol (30 mL). To this mixture was added N-Ethoxycarbonyl-2-ethoxy- 1 ,2-dihy droquinoline (992 mg, 4.0 mol). The reaction flask was wrapped in foil and the hood lights were turned off, while the reaction wns stirred at room temperature for 48 hours. (1046) [0558] The reaction mixture was evaporated to dryness and the resulting solid was titurated with ether. The suspension was stirred overnight in ether, then filtered to give a yellow solid. The solids were again washed with ether to give 990 mg for a 87% yield. MS (ESI): mie 572.66 (Mi l) , 573, (M + Na)+, 595.

85%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃; for 36h;Darkness; Inert atmosphere;	Fmoc-Val-Cit-PABOH 2. To a solution of Fmoc-protected dipeptide 1 (0.30 g, 0.60 mmol) in CH2Cl2/MeOH (2: 1 , 9 mL) was added P-aminobenzyl alcohol (0.12 g, 0.98 mmol ) and EEDQ (0.24 g, 0.98 mmol), and the reaction mixture was stirred in the dark for 1.5 d. The solvents were evaporated, and the resultant was triturated with Et20 (25 mL). The resulting suspension was sonicated for 20 min and left to stand for 30 min. The crude product was collected by filtration and then purified by flash chromatography using a pre-packed 50 g silica column [solvent A: MeOH; solvent B: CH2C12; gradient: 0%A / 100%B (1 CV), 0%A / 100%B -? 20%A / 80%B (10 CV), 20%A / 80%B (2 CV); flow rate: 40 mL/min; monitored at 254 and 280 nm] to afford Fmoc-protected compound 2 (0.31 g, 0.51 mmol, 85% yield) as a brown solid. [000188] NMR (500 MHz, DMSO-d6) 6 10.00 (1 H, s), 8.13 (1 H, d, J = 7.7 Hz), 7.92 (2H, d, J = 7.5 Hz), 7.81 - 7.71 (2H, m), 7.57 (2H, d, J= 8.4 Hz), 7.49 - 7.40 (3H, m), 7.35 (2H, t, J= 7.4 Hz), 7.26 (2H, d, J = 8.3 Hz), 5.99 (1 H, t, J = 6.5 Hz), 5.43 (2H, s), 5.12 (1 H, t, J= 5.6 Hz), 4.45 (2H, d, J= 5.4 Hz), 4.32 (1H, d,J= 10.1 Hz), 4.29 - 4.19 (3H, m), 4.00 - 3.88 (1H, m), 3.12 - 2.91 (2H, m), 2.09 - 1.94 (1H, m), 1.80-1.31 (4H, m), 0.90 (3H, d, .7=6.6 Hz), 0.88 (3H, d,J=6.7 Hz). [000189] I3C NMR (125 MHz, DMSO-d6) delta 171.7, 170.9, 159.3, 156.6, 144.4, 144.2, 141.2, 138.0, 137.9, 128.1, 127.6, 127.4, 125.8, 120.6, 119.3, 66.2, 63.1, 60.6, 47.2,30.9,30.0, 27.3, 19.7, 18.8, 15.0.
82%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; at 20℃; for 36h;	Fmoc-val-cit (1 eq),Add 2 eq of p-aminobenzyl alcohol (2 eq) to DMC / MeOH (2: 1), add EEDQ (2 eq) and shake for 1.5 days at room temperature.After completion of the reaction, the solvent is dried and precipitated with ether. Repeat after filtering with Ether. Yield: yellow solid 82%.
80%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In water; ethyl acetate; N,N-dimethyl-formamide; at 0 - 5℃;	Fmoc-Val-Cit (1 eq.), HATH (1.4 eq.) were solubilized in a mixture of anhydrous N,N-Dimethylformamide (9.5 vol.) and Ethyl acetate (5 vol.) at 20C. The reaction mixture was then cooled to 0-5C. Separately, a solution of 4-Aminobenzyl alcohol (1.5 eq.) in Ethyl acetate (2 vol.) and anhydrous N,N-Dimethylformamide (0.5 vol.) was prepared. A solution of N,N-Diisopropylethylamine (1.4 eq.) in Ethyl acetate (2 vol.) was also prepared. Water (1 vol.) was added to the cooled Fmoc-Val-Cit/HATU solution before adding the 4- Aminobenzyl alcohol solution quickly. Immediately thereafter, the DIPEA solution was added over 25-35 minutes. The reaction mixture was stirred at 0-5C for 1-2 hours until reaction was complete. Pre-chilled Methyl tert-butyl ether (20 vol.) was then added over 10 minutes and the resulting mixture was stirred for 1-3 hours. Solids were filtered, washed and dried under vacuum. Solids were re-slurried in Acetonitrile (20 vol.), filtered, washed and dried under vacuum (80% yield). MS: m/e 602 (MH)+, 624 (M+Na)+.
77%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 40℃;	Step 3 Synthesis of (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (92) To the suspension of compound 90 (70 g, 0.141 mol) in DCM/MeOH (1 L/500 mL) was added compound 91 (34.7 g, 0.282 mol) followed by EEDQ (69.7 g, 0.282 mol). The mixture was stirred at 40 C. overnight. The reaction mixture was filtered and the wet cake was suspended in EtOAc/TBME (500 mL/200 mL) and stirred for 30 min, then filtered. The solid was washed with EtOAc/TBME to provide compound 92 as off-white solid 65 g (77%). 1H NMR (400 MHz, DMSO-d6) delta=9.98 (s, 1H), 8.11 (d, 1H), 7.87 (d, 2H), 7.77 (m, 2H), 7.52 (d, 2H), 7.39 (m, 3H), 7.30 (m, 2H), 7.21 (d, 2H), 5.97 (m, 1H), 5.41 (s, 2H), 5.10 (m, 1H), 4.42 (m, 3H), 4.22 (m, 3H), 3.90 (m, 1H), 2.93 (m, 2H), 1.98 (m, 1H), 1.50 (m, 2H), 1.30 (m, 2H), 0.84 (m, 6H).
76%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃;	A solution of compound 28 (1 g, 2.01 mmol, leq) andp-aminobenzyl alcohol (273 mg, 2.21 mmol, 1.1 eq) in a mixture of DCM/MeOH (20 mL/10 mL) was treated with EEDQ (996 mg, 4.03 mmol, 2 eq). The mixture was stirred in the dark at room temperature overnight. The solvents were removed under vacuum and the resulting solid residue was triturated with 10 mL of ethyl ether. The solid was collected by filtration and washed with ethyl ether to yield the product (925 mg, 76% yield): 1H NMR (DMSO-
65%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃; for 16h;Darkness;	EEDQ (840 mg, 3.4 mmol) is added to a solution containing compound [12] (870 mg, 1 .7 mmol) and p-aminobenzyl alcohol (227 mg, 1 .8 mmol) in dichloro- methane/methanol 2:1 (15 mL). The reaction is left in the dark at room temperature for 16 hours. The solvents are removed, and the resulting solid residue filtrated using diethyl ether to give product [14] as a white solid, 660 mg (65% yield). MS: m/z 624 [M+Na]+.1H NMR (400 MHz, DMSO) delta 10.00 (bs, 1 H), 8.13 (m, 4H), 7.92 (d, J = 7.3 Hz, 2H), 7.76 (d, J = 7.6 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.51 - 7.10 (m, 2H), 6.02 (s, 1 H), 5.43 (m, 4H), 5.13 (s, 1 H), 4.47 (s, 3H), 4.31 (m 4H), 3.13 - 2.74 (m, 2H), 2.03 (s, 1 H), 1 .83 - 1 .55 (m, 2H), 1 .43 (s, 2H), 0.90 (d, J = 6.7 Hz, 6H).13C NMR (101 MHz, DMSO) delta 171 .2, 170.4, 158.93, 156.15, 144.6, 143.8, 140.7, 137.5, 127.6, 127.2 (2C) 125.3, 120.1 (2C), 1 18.9, 65.7, 62.6, 60.1 , 53.0, 46.7, 31 .0, 30.5, 26.7, 19.6, 18.7.
59%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃; for 15h;	b) Fmoc-Val-Cit-PABA (32) A solution of Fmoc-Val-Cit-OH 31 (600 mg, 1.21 mmol), 4-aminobenzyl alcohol (298 mg, 2.42 mmol) and 2-Ethoxy-1-ethoxycarbonyl-1 ,2-dihydroquinoline (598 mg, 2.42 mmol) in CH2CI2/MeOH (12.6 ml_, 2:1 ) was stirred at rt for 15 h. Upon completion, the mixture was diluted with Et20 (30 ml_), sonicaated briefly, filtered and washed with Et20 to yield Fmoc- Val-Cit-PABC (428 mg, 0.710 mmol, 59%) as an off-white solid
	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; In methanol; dichloromethane; at 20℃;Darkness;	The reaction product of reaction step b (7.6 g, 15.3 mmol) and PABOH (3.76 g, 30.6 mmol) were dissolved in a mixture of 140 mL of CH2Cl2 and 70 mL of CH3OH.EEDQ (7.5 g, 30.6 mmol) was added in the dark.Stirring at room temperatureReaction, after the reaction is completed, spin the reaction solution,Wash with ether,Filter by suction.

Reference： [1]International Journal of Molecular Sciences,2017,vol. 18
[2]Patent: CN107789630,2018,A .Location in patent: Paragraph 0073; 0074; 0075
[3]Patent: CN108743968,2018,A .Location in patent: Paragraph 0016; 0017; 0018
[4]Patent: WO2020/14541,2020,A2 .Location in patent: Paragraph 0546; 0551; 0557-0558
[5]Patent: WO2017/66668,2017,A1 .Location in patent: Paragraph 000187-000189
[6]Journal of Controlled Release,2012,vol. 160,p. 618 - 629
[7]Patent: KR2017/41562,2017,A .Location in patent: Paragraph 0431-0432
[8]Patent: WO2019/108797,2019,A1 .Location in patent: Paragraph 0114; 0119
[9]Patent: US2016/271270,2016,A1 .Location in patent: Paragraph 0379; 0382
[10]Patent: WO2008/34124,2008,A2 .Location in patent: Page/Page column 79
[11]Patent: WO2018/178060,2018,A1 .Location in patent: Page/Page column 64; 65; 67
[12]Patent: WO2020/25108,2020,A1 .Location in patent: Page/Page column 48-49
[13]Patent: WO2014/80251,2014,A1 .Location in patent: Sheet 16/23
[14]Bioconjugate Chemistry,2015,vol. 26,p. 2261 - 2278
[15]Nature Communications,2017,vol. 8
[16]Patent: CN109200291,2019,A .Location in patent: Paragraph 0051; 0063; 0067

3
[ 159858-21-6 ]
2BrH*C₃₀H₃₀BrN₅O₃ [ No CAS ]
[ 1037796-59-0 ]

Yield	Reaction Conditions	Operation in experiment
71%	With triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.75h;	6 Compound 19. Compound 10 (25 mg, 0.033 mMoles, 2 HBr Salt)) was reacted with compound D of Example 5 (21.5 mg, 0.043 mMoles) in 2.5 mL DMF in the presence of HATU (16.5 mg, 0.0433 mMoles) and TEA (10-15 μL) for 45 minutes. The solvent was evaporated and crude purified by reverse phase HPLC to give 25 mg of Compound 17. (71% yield). MS: 1067.0. Compound 17 (0.0187 mMoles) was deprotected with 5% piperidine in DMF (3 mL) in 45 minutes. The solvent was evaporated and the residue washed with diethyl ether to give 18 (MS: 845.2). To a Solution of 0.00935 mMoles of 18 in 3 mL DMF was added Mal-dPEG4-NHS ester (10 mg, 0.019 mMoles) in DCM 1 mL, followed by TEA (5 μL). After 30 minutes the solvents were evaporated and the crude purified by Reverse Phase HPLC to give 5.2 mg of pure Compound 19 (MS: 1243.2, 1266.8 and 1281.2)
71%	With triethylamine; HATU In N,N-dimethyl-formamide for 0.75h;	5 Compound 10 (25mg, 0.033 mMoles, 2HBr Salt)) was reacted with compound D of Example 5 (21.5 mg, 0.043 mMoles) in 2.5 mL DMF in the presence of HATU (16.5 mg, 0.0433 mMoles) and TEA (10-15 μL) for 45 minutes. The solvent was evaporated and crude purified by reverse phase HPLC to give 25 mg of Compound 17. (71 % yield). MS: 1067.0.

Reference： [1]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - US2010/145036, 2010, A1 Location in patent: Page/Page column 77; 78
[2]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - WO2008/103693, 2008, A2 Location in patent: Page/Page column 100

4
[ 159858-21-6 ]
[ 159857-79-1 ]

Reference： [1]Patent: WO2014/80251,2014,A1
[2]Patent: WO2017/66668,2017,A1
[3]International Journal of Molecular Sciences,2017,vol. 18
[4]Patent: CN107789630,2018,A
[5]Patent: WO2018/178060,2018,A1
[6]Patent: CN108743968,2018,A
[7]Patent: CN109200291,2019,A
[8]Patent: WO2019/108797,2019,A1

5
[ 159858-21-6 ]
(S,E)-N-(4-(aminomethyl)phenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide [ No CAS ]
(9H-fluoren-9-yl)methyl(S)-1-((S)-1-(4-(N-((S,E)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enoyl)sulfamoyl)benzylamino)-1-oxo-5-ureidopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate In dichloromethane at 0℃; for 0.0833333 - 0.333333h;	Example 1 GENERAL PROCEDURE 6: HATU MEDIATED PEPTIDE BOND FORMATION To a stirred solution of the carboxylic acid in a minimal amount of dichioromethane or N,N-dimethylformamide or mixture thereof, at 0°C was added HATU(1.05-1.2 equivalents) and either N,N-diisopropylamine (2-4 equivalents) or 2,4,6-collidine (2-4 equivalents). Stirring was continued for a brief induction period (5-20 minutes) at which time the reaction was charged with a solution of the amine in dichioromethane. The reaction was allowed to warm to room temperature and monitored for progress by HPLC-MS. Upon completion, volatiles were removed under reduced pressure and the residual material waspurified by silica gel chromatography or reverse phase HPLC to furnish amide in adequate purity. CompoundA-6: (9H-fluoren-9-yl)methyl (S)-1-((S)-1-(4-(N-((S,E)-2,5-dimethyl-4-((S)- N,3,3-trimethyl-2-((S)-3-methvl-2-(melhylamino)-3-phenylbutananzido)butanamido)hex-2- enoyl)sufamoyl)benzylamino)-1-oxo-5-ureidopentan-2-ylamino)-3-methyi-1-oxobutan-2- ylcarbamate Synthesized from (S,E)-N-(4-(aminomethyl)phenylsulfonyl)-2,5-dimethyl-4- ((S)-N,3 ,3 -trimethyl-2-((S)-3 -methyl-2-(rnethylamino)-3 -phenylbutanarnido)butanamido)hex-2- enamide and Fmoc-Val-Cit-OH according to General Procedure 6 with minor contamination by D1PEA and AcOH. Material used “as is” in the subsequent step.C60H81N9010S calcd. [M+H] 1120.58; found [M+H] 1120.68.

Reference： [1]Current Patent Assignee: ZYMEWORKS INC - WO2015/95953, 2015, A1 Location in patent: Page/Page column 113; 124

6
[ 159858-21-6 ]
(S)-tert-butyl 5-(4-aminobenzyl)-3,3-dimethyl-2-oxopyrrolidine-1-carboxylate [ No CAS ]
C₄₄H₅₆N₆O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 2,6-dimethylpyridine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 1.5h;	7 (0294) To a solution of compound 61 (382 mg, 1.20 mmol) and (S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid 62 (CAS Reg. No. 557095-84-8, 596 mg, 1.20 mmol) in DMF (5 mL) at 0° C. were added HATU (593 mg, 1.560 mmol) and 2,6-dimethylpyridine (193 mg, 1.800 mmol). The reaction mixture was stirred at RT for 1.5 h. Cold water (50 mL) was added. The solid formed was collected by filtration, washed with water, and dried under vacuum to give a tan solid that was used for next reaction directly. MS (ESI+) m/z 797.5 (M+H)+.

Reference： [1]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - US2016/130299, 2016, A1 Location in patent: Paragraph 0294

7
[ 159858-21-6 ]
4-(amino)-1,6-heptanediamide bis-AHX-DM₁ trifluoroacetate [ No CAS ]
4-(Fmoc-Val-Cit-amido)-1,6-heptanediamide bis-AHX-DM₁ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
16.9 mg	With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 0℃; for 1.5h;	8.4 Stock solutions of compound 8A (20.0 mg) in DMF (500 μ) and HATU (40.0 mg) in DMF (400 μ) were prepared. To a stirred solution of compound 1A (14.0 mg) in DMF (700 μ) was added aliquots of compound 8A stock solution (126.9 μ) and HATU stock solution (77.8 μ). The reaction solution was cooled to 0 °C before the addition of DIPEA (4.11 μ). The solution was stirred at 0 °C for 50 min before further aliquots of compound 8A stock solution (126.9 μ), HATU stock solution (77.8 μ and DIPEA (4.11 μ) were added. The solution was stirred for 40 min at 0 °C. The reaction solution was purified by reverse phase C18-column chromatography eluting with buffer A (v/v): water:0.05% trifluoroacetic acid and buffer B (v/v): acetonitrile:0.05% trifluoroacetic acid (100:0 v/v to 0: 100 v/v). The solvent was removed by lyophilisation to give 4-(Fmoc-val-cit-amido)-l,6-heptanediamide bis-AHX-DMl compound 9A (assumed quantitative yield, 16.9 mg) as an off-white solid m/z [M+2H-2(H20)]2+ 1055 (100%).

Reference： [1]Current Patent Assignee: WELSH, CARSON, ANDERSON & STOWE - WO2016/63006, 2016, A1 Location in patent: Page/Page column 38; 39

8
[ 159858-21-6 ]
[ 863971-53-3 ]

Reference： [1]Patent: US2016/271270,2016,A1
[2]Patent: WO2020/25108,2020,A1

9
[ 159858-21-6 ]
tert-butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine-1-carboxylate [ No CAS ]
C₃₉H₅₂N₆O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
24.8%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid With N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 1h; Stage #2: tert-butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine-1-carboxylate With N-ethyl-N,N-diisopropylamine at 20℃;	A mixture of EC2405 (42.7 mg, 0.20 mmol), 2-aminoethan-1-ol (12.8 tl, 0.21 mmol) and molecular sieves in toluene (1 ml) was stuffed at room temperature for 1.5 hours to generate the tert-butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine-1-carboxylate in situ. A mixture of Fmoc-Val-Cit-OH (0.11 g, 0.22 mmol) and HATU (0.12 g, 0.30 mmol) in DMF (2 ml) was stirred at room temperature for 1 hour, then DIEA (0.11 ml, 0.61 mmol) was added. The tertbutyl (2S)-4-methylene-2- (oxazolidin-2-yl)pyrrolidine- 1 -carboxylate reaction mixture was transferred into this reaction mixture and stirred at room temperature overnight. The crudeproduct was purified with CombiFlash in 0-20% MeOH/DCM to afford 40 mg of EC2369 in24.8 % yield. LCMS: [M+H] mlz = 733.73.

Reference： [1]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2016/148674, 2016, A1 Location in patent: Page/Page column 124; 125

10
[ 13594-51-9 ]
2,5-dioxopyrrolidin-1-yl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-valinate [ No CAS ]
[ 159858-21-6 ]

Yield	Reaction Conditions	Operation in experiment
53%	With sodium hydrogencarbonate; In 1,2-dimethoxyethane; water; at 25 - 30℃; for 48.0h;Cooling with ice;	Step 2 Synthesis of (S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid (90) To a solution of compound 89 (40.14 g, 0.229 mol) and NaHCO3 (19.23 g, 0.229 mol) in water (750 mL) was added the solution of compound 88 (100 g, 0.229 mol) in DME (750 mL) dropwise under ice-bath. During the addition, a white suspension was formed. Additional THF (400 mL) was added to improve the solubility. After addition, the solution was stirred at 25-30 C. for 2 days. To the reaction was added saturated aq. K2CO3 to adjust pH to 8-9, then extracted with EtOAc (500 mL*5). The aqueous layer was adjusted pH to 3-4 with aq. citric acid. A gelatinous material was formed and filtered. The wet cake was dissolved in THF (1.5 L). Methanol was added until the solid was dissolved. The solution was concentrated in vacuum to remove 30% of solvent and then cooled to room temperature. TBME (2 L) was added to the solution and the mixture was stirred at room temperature overnight. The mixture was filtered and the wet cake was dried in vacuum to give compound 90 as a white solid 60 g (53%).

Reference： [1]Patent: US2016/271270,2016,A1 .Location in patent: Paragraph 0379; 0381

11
[ 159858-21-6 ]
C₁₄H₂₁N₅O₂ [ No CAS ]
C₂₅H₄₁N₉O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid; C₁₄H₂₁N₅O₂ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.166667h;	3 Preparation of compound 38: To compound 37 (261 mg, 0.52 mmol) in 6 mL of DMF was added HATU (217 mg,0.57 mmol), DIEA (362 giL, 2.08 mmol), and amine 36 (213 mg, 0.52 mmol). The mixturewas stirred for 30 mm, then 400 pL of piperidine was added and stirred for 10 mm. The mixture was evaporated and purified by HPLC to give compound 38 (171 mg, 60%). MS mlz 548.3 (M+H).
60%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid; C₁₄H₂₁N₅O₂ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.166667h;	1 Synthesis of Compound 3 Compound 2 (261 mg, 0.52 mmol) was dissolved in 6 mE of DMF. Then HATU (217 mg, 0.57 mmol), DIEA (362 tE, 2.08 mmol), and amino compound 1(213 mg, 0.52 mmol) were added. After stirred for 30 mm, then 400 pL piperidine was added and stirred for another 10 mm. The reaction solution was concentrated and directly purified by HPEC to obtain compound 3 (171 mg, 60%). MS mlz 548.3 (M+H).

Reference： [1]Current Patent Assignee: SORRENTO THERAPEUTICS INC - WO2016/123412, 2016, A1 Location in patent: Paragraph 11; 12
[2]Current Patent Assignee: HANGZHOU ADCORIS BIOPHARMA - US2019/91345, 2019, A1 Location in patent: Paragraph 0154; 0155

12
[ 159858-21-6 ]
C₁₄H₂₁N₅O₂ [ No CAS ]
C₃₅H₄₂N₈O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid; C₁₄H₂₁N₅O₂ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Stage #2: With trifluoroacetic acid In dichloromethane for 0.5h;	8 To compound 37 (130 mg, 0.26 mmol) in 3 mL of DMF was added HATU (110 mg,0.29 mmol), DIEA (175 giL, 1 mmol), and amine 36 (110 mg, 0.27 mmol). The mixture was stirred for 30 mm, then concentrated to dryness. The residue was then treated with TFA/DCM (1/4, v/v, 5 mL) for 30 mm. The mixture was evaporated and purified by HPLC to givecompound 66 (108mg, 65%). MS mlz 670.5 (M+H).

Reference： [1]Current Patent Assignee: SORRENTO THERAPEUTICS INC - WO2016/123412, 2016, A1 Location in patent: Page/Page column 16

13
[ 159858-21-6 ]
[ 159857-80-4 ]

Reference： [1]Patent: WO2017/66668,2017,A1
[2]International Journal of Molecular Sciences,2017,vol. 18
[3]Patent: CN107789630,2018,A
[4]Patent: CN108743968,2018,A
[5]Patent: CN109200291,2019,A
[6]Patent: WO2019/108797,2019,A1
[7]Patent: WO2020/14541,2020,A2

14
[ 372-75-8 ]
[ 68858-20-8 ]
[ 159858-21-6 ]

Yield	Reaction Conditions	Operation in experiment
70%	Stage #1: Fmoc-Val-OH With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 16h; Stage #2: Citrulline With sodium hydrogencarbonate In tetrahydrofuran; 1,2-dimethoxyethane; water at 20℃; for 16h;
69%	Stage #1: Fmoc-Val-OH With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 16h; Stage #2: Citrulline With sodium hydrogencarbonate In tetrahydrofuran; 1,2-dimethoxyethane; water at 20℃; for 16h;	3.2.3 Synthesis of [(9h-fluorene-9-yl) methoxy] carbonyl}-l-pentyl-l-alanine (6) General procedure: The Fmoc-protected l-valine (compound 5) (30g, 88.5mmol) was completely dissolved in tetrahydrofuran. N-hydroxysuccinimide (10.2g, 88.5mmol) and Dicyclohexylcarbodiimide (18.3g, 88.5mmol) were added to the reaction solution, and the reaction was stirred at room temperature for 16h. The reaction solution was transferred to 0°C. After stirring for 2h, the solid impurities were removed via filtration. The filtrate was concentrated under a reduced pressure to obtain the glassy solid crude product. The crude product was then dissolved in a mixed solvent of 150mL tetrahydrofuran and 200mL of 1,2-dimethoxyethane. An aqueous sodium bicarbonate solution of l-alanine (8.7g, 97.4mmol) was then added. The reaction was stirred at room temperature for 16h. The reaction solution was poured into 350mL of a 15% citric acid aqueous solution, and the solid and dry were filtered out. Furthermore, the solid was dispersed in ether solvent and ultrasonically filtered. The process was repeated three times. Finally, 21.4g of compound 6 were obtained at a 59% yield.

Reference： [1]Wang, Yanming; Fan, Shiyong; Zhong, Wu; Zhou, Xinbo; Li, Song [International Journal of Molecular Sciences, 2017, vol. 18, # 9]
[2]Xiao, Dian; Luo, Longlong; Li, Jiaguo; Wang, Zhihong; Liu, Lianqi; Xie, Fei; Feng, Jiannan; Zhou, Xinbo [Bioorganic Chemistry, 2021, vol. 116]

15
C₇H₁₅N₃O₂ [ No CAS ]
[ 130878-68-1 ]
[ 159858-21-6 ]

Yield	Reaction Conditions	Operation in experiment
65%	With sodium hydrogencarbonate; In tetrahydrofuran; 1,2-dimethoxyethane; water; at 20℃; for 24h;	Add in 20ml THFCit4.0g(1.05 eq) and 60 ml aqueous solution of sodium bicarbonate (NaHCO3 2g,1.05eq).Another 22.35mmol Fmoc-Val-OSu dissolved in 60ml DME,Then add it to the reaction solution.Reaction solution in the roomThe reaction was stirred at the temperature for 24 hours.After the reaction is completed,Add 15% citric acid aqueous solution to the system, 110mlThen use EA extractionTake twice,Combine organic layers,Concentrate under reduced pressure to give a white solid.Add 100 ml methyl tert-butyl ether to white solidwash,filter,The filter cake was dried under reduced pressure at 40C for 4 hours to obtain 4.83 g of product.Yield 65%.

Reference： [1]Patent: CN107789630,2018,A .Location in patent: Paragraph 0070; 0071; 0072

16
[ 159858-21-6 ]
tert-butyl (S)-1-((S)-1-(((S,E)-6-(4-aminophenylsulfonamido)-2,5-dimethyl-6-oxohex-4-en-3-yl)(methyl)amino)-3,3-dimethyl-1-oxobutan-2-ylamino)-3-methyl-1-oxo-3-phenylbutan-2-yl(methyl)carbamate [ No CAS ]
tert-Butyl ((S)-1-(((S)-1-(((S,E)-6-(4-((S)-2-((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)phenylsulfonamido)-2,5-dimethyl-6-oxohex-4-en-3-yl)(methyl)amino)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxo-3-phenylbutan-2-yl)(methyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid With N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate at 0℃; Stage #2: tert-butyl (S)-1-((S)-1-(((S,E)-6-(4-aminophenylsulfonamido)-2,5-dimethyl-6-oxohex-4-en-3-yl)(methyl)amino)-3,3-dimethyl-1-oxobutan-2-ylamino)-3-methyl-1-oxo-3-phenylbutan-2-yl(methyl)carbamate In dichloromethane at 0 - 20℃;	1 General Procedure 3: HA TU Mediated Peptide Bond Formation General procedure: To a stirred solution of the carboxylic acid in a minimal amount of dichloromethane or N,N-dimethylformamide or mixture thereof, at 0° C. was added HATU (1.05-1.2 equivalents) and either N,N-diisopropylamine (2-4 equivalents) or 2,4,6-collidine (2-4 equivalents). Stirring was continued for a brief induction period (5-20 minutes) at which time the reaction was charged with a solution of the amine in dichloromethane. The reaction was allowed to warm to room temperature and monitored for progress by HPLC-MS. Upon completion, volatiles were removed under reduced pressure and the residual material was purified by silica gel chromatography or reverse phase HPLC to furnish amide in adequate purity.

Reference： [1]Current Patent Assignee: VAR2 PHARMACEUTICALS APS; ZYMEWORKS INC - US2018/193473, 2018, A1 Location in patent: Paragraph 0347; 0360-0361

17
[ 159858-21-6 ]
[ 94838-55-8 ]
C₃₈H₄₈N₆O₇ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74.4%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 24h;	Taking 18 g compound 32 is added to 500 ml of the reaction bottle, for 200 mLDMF after dissolving, adding 8 g (1.0 eq) 4 - [(N-tert-butoxycarbonyl) aminomethyl] aniline, HATU20g (1.5 eq), DIPEA (18 ml, 3 eq), stirring at room temperature for 24 h, TLC detection raw material after the reaction is complete, adding water 200 ml, dichloromethane 200 ml, stirring 10 min after, separating the organic layer, then washed with water twice, each 50 ml, collecting the organic layer, after drying with anhydrous sodium sulfate, filtering the concentrated, shall be brown oily matter, to the oily adding methyl tert-butyl ether 200 ml, stirring 30 min after, the solid washed, filtered, the filter cake is a tert-butyl ether washing 2 times, each 50 ml, collecting filter cake, 50 °C in the vacuum drying box drying to obtain the brown solid 18.9 g, yield 74.4percent.

Reference： [1]Patent: CN109125736,2019,A .Location in patent: Paragraph 0113; 0130; 0135; 0136

18
[ 159858-21-6 ]
tert-butyl [(1S)-2-(4-aminophenyl)-1-(1,3-thiazol-2-yl)ethyl]carbamate [ No CAS ]
C₃₇H₄₃N₇O₅S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
67%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid; tert-butyl [(1S)-2-(4-aminophenyl)-1-(1,3-thiazol-2-yl)ethyl]carbamate With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Stage #2: With trifluoroacetic acid In dichloromethane for 0.166667h;	9 Preparation of Compound 35 HATU (110 mg, 0.29 mmol), DIEA (181 uL, 1.04 mmol) and Compound 34 (83 mg, 0.26 mmol) were added to the solution of Compound 2 (131 mg, 0.26 mmol dissolved in 4 mE DMF) in turn. Afier stirred for 30 mm, the solution was evaporated under vacuum. The residue was dissolved in 2 mE of DCM and then 1 mE of TFA was added and stirred for 10 mm. The solution was evaporated under vacuum and purified by HPLC to obtain Compound 35 (118 mg, 67%). MS mlz 698.4 (M+H).

Reference： [1]Current Patent Assignee: HANGZHOU ADCORIS BIOPHARMA - US2019/91345, 2019, A1 Location in patent: Paragraph 0180; 0181

19
[ 159858-21-6 ]
C₁₄H₂₁N₅O₂ [ No CAS ]
C₃₅H₄₃N₉O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid; C₁₄H₂₁N₅O₂ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Stage #2: With trifluoroacetic acid In dichloromethane for 0.5h;	2 Example 2 Synthesis of Compound 11 Compound 2 (130 mg, 0.26 mmol) was dissolved in 3 mE of DMF. Then HATU (110mg, 0.29 mmol), DIEA (175 tE, 1 mmol), and amino compound 1 (110 mg, 0.27 mmol) were added. The reaction solution was stirred for 30 mi and evaporated to dryness in vacuo. The residue was dissolved in TFAdichloromethane (1/4, v/v, 5 mE) and stirred for 30 mm. The reaction solution was evaporated to dryness under reduced pressure and purified by HPEC to obtain compound 8 (108 mg, 65%). MS mlz 670.5 (M+H).

Reference： [1]Current Patent Assignee: HANGZHOU ADCORIS BIOPHARMA - US2019/91345, 2019, A1 Location in patent: Paragraph 0158; 0159

20
[ 159858-21-6 ]
tert-butyl N-[(4bS,8S,8aR)-8-([(1S,4aS,10aR)-6-amino-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]formamido}carbonyl)-4b,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthren-3-yl]carbamate [ No CAS ]
tert-butyl N-[(4bS,8S,8aR)-8-([(1S,4aS,10aR)-6-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-(carbamoylamino)pentanamido]-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]carbonyl}carbamoyl)-4b,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthren-3-yl]carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
38%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 0.0833333h; Stage #2: tert-butyl N-[(4bS,8S,8aR)-8-([(1S,4aS,10aR)-6-amino-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]formamido}carbonyl)-4b,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthren-3-yl]carbamate In N,N-dimethyl-formamide at 20℃; for 20h; Stage #3: With piperidine In N,N-dimethyl-formamide at 20℃; for 6h;	11-5.5a Intermediates 102a-b General procedure: To a solution of acid (Fmoc-Val-Ala-OH (101a, 1.2 equiv.) or Fmoc-Val-Cit-OH (101b, 1.2 equiv.) in DMF were added HATU (1.2 equiv.) and DIPEA (2.0-3.0 equiv.) at RT. After the mixture was stirred at RT for 5 min, compound 12b (1.0 equiv.) was added. The resulting mixture was stirred at RT for 4-20 h until the amine was consumed according to LCMS. To the mixture was then added piperidine (excess), and the mixture was stirred at RT for 1-6 h until Fmoc was totally removed, as monitored by LCMS. The reaction mixture was filtered through a membrane and the filtrate was directly purified by prep-HPLC (method B) or reverse phase flash chromatography to give compound 102 (38-72% yield) as a white solid.

Reference： [1]Current Patent Assignee: REGENERON PHARMACEUTICALS INC - WO2019/217591, 2019, A1 Location in patent: Paragraph 0539; 0540; 0541

21
[ 159858-21-6 ]
[ 74124-79-1 ]
C₃₀H₃₅N₅O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine In N,N-dimethyl-formamide at 20℃; for 10h;	6 Example 6: Synthesis of SDM-274 A mixture of Fmoc-Val-Cit (9.6 mg, 0.019 mmol), disuccinimidyl carbonate (5.44 mg, 0.02lmmol) and Et3N (2.68 m, 0.019 mmol) was stirred at room temperature for 10 h. Then Gly-MMAF (15.2 mg, 0.019 mmol) and Et3N (8.0 m, 0.058 mmol) was added and the mixture was stirred at room temperature overnight. The crude product was purified by prep HPLC. Compound 3 was obtained as a white powder after lyophilization (12.8 mg, 52 %). MS (ESI): m/e 1267.5 [M+H]+.

Reference： [1]Current Patent Assignee: AVELAS BIOSCIENCES - WO2019/204364, 2019, A1 Location in patent: Paragraph 0348

22
[ 159858-21-6 ]
5-amino-2-(hydroxymethyl)-N-methylbenzamide [ No CAS ]
C₃₅H₄₂N₆O₇ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
53%	With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In tetrahydrofuran at 25℃;	6 Compound 3. To a solution of (S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)-amino)-3-methylbutanamido)-5-ureidopentanoic acid (Fmoc-Val-Cit, 1.681 g, 3.39 mmol) and compound 2 (1.22 g, 6.77 mmol) in THF (5 mL) was added EEDQ (1.674 g, 6.77 mmol). The reaction mixture was stirred at RT overnight. LCMS (M+H-H2O=659.3) showed product formation. The reaction was directly purified on a COMBIFLASH column using 40 g silical gel and eluting with 0-100% MeOH/DCM to yield compound 3 (53% yield).

Reference： [1]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - US2019/365915, 2019, A1 Location in patent: Paragraph 0133-0134

23
[ 159858-21-6 ]
C₄₂H₅₄N₂O₇S₂ [ No CAS ]
C₆₈H₈₄N₆O₁₂S₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
67.8%	Stage #1: (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In methanol; dichloromethane at 0℃; for 1h; Stage #2: C₄₂H₅₄N₂O₇S₂ With triethylamine In methanol; dichloromethane	1.3 3. Synthesis of Fmoc-valine-citrulline-garcinic acid (Fmoc-VC-SS-GA) Fmoc-Val-Cit (0.5 g, 1 mmol) was dissolved in 50 mL of dichloromethane and 10 mL of methanol, cooled to 0 ° C, and EDCI (0.25 g, 1.3 mmol) and HOBT (0.18 g, 1.3 mmol) were added. The resulting mixture was After activation at 0 ° C for 1 h, a dichloromethane solution (30 mL) of GA-SS-NH2 (1.69 g, 7.5 mmol) and triethylamine (267 μL, 2 mmol) were added, and the resulting mixture was stirred overnight. After the reaction was completed, the solution was concentrated under reduced pressure, 100 mL of ice water was added, and stored at 4 ° C. overnight, filtered, washed with water three times, and dried under vacuum. Purification by column chromatography (methanol: dichloromethane 1:11) gave Fmoc-VC-SS-GA in a yield of 67.8%.

Reference： [1]Current Patent Assignee: LIAONING UNIVERSITY - CN110604820, 2019, A Location in patent: Paragraph 0054; 0066-0068

24
[ 159858-21-6 ]
[ 159858-33-0 ]

Yield	Reaction Conditions	Operation in experiment
80%	With DEA In N,N-dimethyl-formamide at 20℃; for 4h;	5 Example 5: Synthesis of Compound 5 VC1000 (5 g, 10 mmol) was dissolved in 50 mL of DMF, 10 mL of DEA was added, and the mixture was stirred at room temperature for 4 hours. LCMS showed that the reaction was complete.The reaction solution was added with 200 mL of methyl tert-butyl ether to make slurry, and filtered to obtain compound 5 (2.2 g, yield 80%).

Reference： [1]Current Patent Assignee: LEVENA SUZHOU BIOPHARMA - CN113813399, 2021, A Location in patent: Paragraph 0150-0152

Related Products

Historical Records

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 159858-21-6 ]

Quality Control of [ 159858-21-6 ]

Related Doc. of [ 159858-21-6 ]

Product Details of [ 159858-21-6 ]

Safety of [ 159858-21-6 ]

Application In Synthesis of [ 159858-21-6 ]

[ 159858-21-6 ] Synthesis Path-Upstream 1~4

[ 159858-21-6 ] Synthesis Path-Downstream 1~24

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry